Research programme: neurokinin 1 receptor antagonists - Merck and Co.

Drug Profile

Research programme: neurokinin 1 receptor antagonists - Merck and Co.

Alternative Names: Hydroisoindoline tachykinin receptor antagonists - Merck; Hydroisoindoline-based human neurokinin-1 receptor antagonists - Merck; L-760735; Tetrahydroindolizinone NK1 antagonists - Merck

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Isoindoles; Pyrroles
  • Mechanism of Action Neurokinin 1 antagonists; Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Chemotherapy-induced nausea and vomiting; CNS disorders; Major depressive disorder

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Chemotherapy-induced-nausea-and-vomiting in United Kingdom
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Chemotherapy-induced-nausea-and-vomiting in USA
  • 01 Sep 2011 Preclinical development for Chemotherapy induced nausea and vomiting is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top